Member Info for GraphiteTech

There will be not much of a gap between design freeze and production, one of the partners already upped production capacity and taken on more staff in anticipation

Watch all the usual low life types give it a big shift now this evening

Grewal is a board member and scientist of Omega

Little tip see whose liked that UK diagnostic tweet.

Omega & Jag Grewal

At Design freeze stage which I suspect is imminent you won't be able to buy these sub 50p.

Could do 50/100% here today with Oryx likely out

The level of understanding some hold confounds me

Looking at yesterday’s trades I reckon they got through the remaining ones at around 3pm.

All ready to blast off today

Often funds hit a point and its cash in time, could be a weighting to overall value, could be a preset target has been hit, could be due to losses elsewhere.

Numerous reasons, funds often don't do what you expect on both sides of the cycle.

Course they are, but likely fast antibody testing is key

I had 50p area for a slice target, now thinking much higher.

So many let their NCYT golden tickets go way too early. Lesson learnt.

100's of millions of tests, Antibody being the UKGov preferred choice and Omega at the centre of it.

Talk of over 200,000 tests per day in May, PCR holds a very important at the front end and this at the back so to speak.

Antibody always has been UKGov preferred route to go with herd immunity, no way you can check herd immunity %%% without such.

That is why we wasted money on faulty tests from China, 17.5m of them.

https://www.abingdonhealth.com/acquisition-concepta-yorkshire-lateral-flow-manufacturing-site-outsource-concepta-manufacturing-requirements/

That link kind of let the cat out of the bag.

The UKGov collaboration between ODX and the others read like a MOU when in fact it was working agreement that is being out into place now hence Abingdon seeking and purchasing extra manufacturing capability.

Omega is the lead element from a size and capacity perspective.

Clearly the UKGov antibody testing strategy is down to them and the others to deliver by May at the latest.

We need these tests to get people tested and back to work, its key 100% to the economy recovering and normality returning.

DYOR on the last RNS, Abingdons news releases and blogs (private co) and the HM Gov papers on the strategy.

All fits all comes together.

Lot easier to move a £15m mcap to £60m than a £300m mcap to £1.2bn

All this 'my Covid19 stock is better than yours' is really starting to **** me off.

Childish beyond belief.

GDR the right sort of market cap to do a WORX style move.

Its a game changer, the capacity, simple manufacturing and freeze dried nature of transport alongside the easy to use testing device that makes it portable sets this apart.

Groover,

Have empathy for your situation but you really cannot take guidance from others on a BB when in a situation like you describe.

I hope GDR does what it is capable of, I expect a price of £1+ soon but we cannot give guarantees.

I would say Covid19 stocks are the only sector I would look at and this appears at the mcap to be one that offers great promise.

So please DYOR and only put in what you can afford to do so.

Best of luck and hope your fortunes change for the better.

Lab Based, High Volume SARS-CoV-2 Diagnostic Test

As the global spread of coronavirus infection increases, it is likely that a variety of diagnostic tools will be needed for direct clinical care via specialist laboratories, central hospital labs and in the community.

It is likely that millions and millions of people will need to be tested, and high throughput central molecular testing will no doubt play a central role. Genedrive will deliver clinically verified, consistent and reproducible assays that are easy to use and can be manufactured and delivered globally in high volume.

Key Design Features:

End-point hybridisation and melt curve analysis

More tolerant of emerging viral mutations than other PCR technologies
Can be performed on standard PCR instrument with analysis phase on a real-time platform
High volume manufacturing capability

> 10,000 tests per hour, 250,000 per week
High Throughput plate format

Compatible with 96-well third party real-time PCR platforms
One-step RT-PCR, with direct in-plate reconstruction using RNA eluate
Freeze-dried reagents

Ambient shipping and storage, long term stability
Ready-to-go format minimises user interactions during setup
96 Reactions per kit (can be used modularly with reduced throughput)
Validated sample types

Nasopharyngeal swabs and Oropharyngeal swabs
Globally accepted gene targets

E and N genes - WHO recommended targets
Internal and positive controls per assay
Regulatory

Aiming for CE mark
PCR Controls

Internal RNA target assay control
Endogenous human RNA control